Chunk #7 — Current Status of Drug Labeling and Pharmacogenomic Testing Guidelines

Source

Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.

Embedded

yes

Text

clinical guidelines for psychiatrists regarding pharmacogenomic testing for CYP2D6 and CYP2C19.19 The authors provided general information about the availability of genetic testing, information about choice of appropriate test, and dose recommendation for antidepressants and antipsychotic drugs metabolized by CYP2D6 and CYP2C19. Their recommendations were designed as dosing or drug selections suggestions based on the results of testing as well as other clinical factors.